Skip to main content
Caplight Logo









Netris Pharma

Netris Pharma

Private
LyonHealthcare & Life Scienceshttps://www.netrispharma.com/

Last Round

Grant

May 28, 2026

Total Funding Raised

$48.64M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Netris Pharma is a biotechnology company that develops anti-cancer therapeutic molecules designed to overcome resistance to oncology treatments.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticaloncologymonoclonal antibodycancer therapynetrin-1clinical-stage biotechdrug resistancesolid tumorsclinical trialsepithelial-to-mesenchymal transitionEMTcancer drug discoveryprecision medicineimmuno-oncologybiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Netris Pharma Comparables

Compare Netris Pharma with similar companies based on industry and business-model similarity.

Netris Pharma comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Medannex Ltd
81%
Compugen Ltd.
78%
Alethia Biotherapeutics
77%

Netris Pharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMay 28, 2026
Series A ExtensionDec 19, 2023
GrantJan 19, 2023
GrantDec 16, 2021
Series ADec 23, 2020

Netris Pharma Investors

Notable investors and investment history

Netris Pharma investors
InvestorRounds
European Innovation Council FundGrant
Eclosion VenturesSeries A
Eurostars SME programmeGrant
Wille Finance AGSeries A
Horizon EuropeGrant
BpifranceSeries A
EIC FundSeries A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 21, 2026

    Monthly visitors increased 33% MoM.

  • Oct 19, 2025

    Results for drug candidate NP137 to be presented at ESMO Congress 2025.

Netris Pharma Filings

Explore SEC and related filing metadata, where available.

Netris Pharma filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Netris Pharma's valuation, stock price, and market status.

Is Netris Pharma a public or private company?

Netris Pharma is a private company.

What is the current stock price of Netris Pharma?

Netris Pharma is a private company with no public stock price. No recent secondary market data is available.

How much is Netris Pharma worth (valuation)?

Valuation information for Netris Pharma is not publicly available.

Can I buy Netris Pharma stock?

Netris Pharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Netris Pharma's last funding round?

Netris Pharma's most recent funding round was Series A Extension on December 19, 2023.

Who are the main investors in Netris Pharma?

Key investors in Netris Pharma include EIC Fund.

Will Netris Pharma IPO soon?

No public IPO plans have been announced for Netris Pharma.

How can I track Netris Pharma secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Netris Pharma's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersLyon
Employee Range13
Year Founded2008
Last FundingMay 28, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?